Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop

Carla J. Greenbaum, Gerald T. Nepom, Lauren K. Wood-Heickman, Diane K. Wherrett, Linda A. DiMeglio, Kevan C. Herold, Jeffrey P. Krischer

Diabetes 2024;73(11):1780–1790

https://doi.org/10.2337/dbi24-0020

Published: 21 August 2024

View article titled, Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop

Meeting Abstracts

70-OR: PROTECT Per-Protocol Analysis—Preserving ß-Cell Function in Children and Adolescents with Newly Diagnosed Stage 3 Type 1 Diabetes (T1D)

KEVAN C. HEROLD, COLIN DAYAN, LUCIENNE CHATENOUD, STEPHEN E. GITELMAN, ZDENEK SUMNIK, KIMBER M. SIMMONS, AGNIESZKA SZYPOWSKA, LAURA KNECHT, ELISABETH NIEMOELLER, WEI TIAN, ELEANOR L. RAMOS

Diabetes 2024;73(Supplement_1):70-OR

https://doi.org/10.2337/db24-70-OR

Published: 14 June 2024

View article titled, 70-OR: PROTECT Per-Protocol Analysis—Preserving ß-Cell Function in Children and Adolescents with Newly Diagnosed Stage 3 Type 1 Diabetes (T1D)

Meeting Abstracts

155-OR: Genetic Variation and Time to Progression in TN10 (Teplizumab)

DOMINIKA A. MICHALEK, SUNA ONENGUT-GUMUSCU, WEI-MIN CHEN, TODD M. BRUSKO, ANDREA STECK, PETER GOTTLIEB, RICHARD A. ORAM, JEFFREY KRISCHER, HEMANG M. PARIKH, MARIA J. REDONDO, KEVAN C. HEROLD, STEPHEN S. RICH

Diabetes 2024;73(Supplement_1):155-OR

https://doi.org/10.2337/db24-155-OR

Published: 14 June 2024

View article titled, 155-OR: Genetic Variation and Time to Progression in TN10 (Teplizumab)

Meeting Abstracts

1301-P: Frequency of Single Autoantibody Positivity (SAB+) Varies by Race/Ethnicity and Area Deprivation Index in Individuals at Risk for Type 1 Diabetes (T1D)

ANANTA ADDALA, SUSANNE M. CABRERA, DAVID D. CUTHBERTSON, INGRID LIBMAN, MUSTAFA TOSUR, ALEJANDRO F. SILLER, LINDA A. DIMEGLIO, KEVAN C. HEROLD, MARIA J. REDONDO, HEBA M. ISMAIL

Diabetes 2024;73(Supplement_1):1301-P

https://doi.org/10.2337/db24-1301-P

Published: 14 June 2024

View article titled, 1301-P: Frequency of Single Autoantibody Positivity (SAB+) Varies by Race/Ethnicity and Area Deprivation Index in Individuals at Risk for Type 1 Diabetes (T1D)

Meeting Abstracts

68-OR: Influence of the Type 1 Diabetes Genetic Risk Score on Response to Immunotherapies for Type 1 Diabetes Prevention

MARIA J. REDONDO, BRIAN N. BUNDY, HEMANG M. PARIKH, LU YOU, TAYLOR M. TRIOLO, LAURIC A. FERRAT, ERIN TEMPLEMAN, MUSTAFA TOSUR, ANDREA STECK, PETER GOTTLIEB, SUNA ONENGUT-GUMUSCU, STEPHEN S. RICH, RICHARD A. ORAM, KEVAN C. HEROLD, JEFFREY KRISCHER

Diabetes 2024;73(Supplement_1):68-OR

https://doi.org/10.2337/db24-68-OR

Published: 14 June 2024

View article titled, 68-OR: Influence of the Type 1 Diabetes Genetic Risk Score on Response to Immunotherapies for Type 1 Diabetes Prevention

Meeting Abstracts

728-P: Experience with Teplizumab in the PROTECT Type 1 Diabetes (T1D) Study during the COVID-19 Pandemic

STEPHEN E. GITELMAN, KEVAN C. HEROLD, KIMBER M. SIMMONS, ZDENEK SUMNIK, LAURA KNECHT, ELISABETH NIEMOELLER, WEI TIAN, GAIL M. COMER, DIANA E. MILLER, ELEANOR L. RAMOS

Diabetes 2024;73(Supplement_1):728-P

https://doi.org/10.2337/db24-728-P

Published: 14 June 2024

View article titled, 728-P: Experience with Teplizumab in the PROTECT Type 1 Diabetes (T1D) Study during the COVID-19 Pandemic

Journal Articles

Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes

Esther Latres, Carla J. Greenbaum, Maria L. Oyaski, Colin M. Dayan, Helen M. Colhoun, John M. Lachin, Jay S. Skyler, Michael R. Rickels, Simi T. Ahmed, Sanjoy Dutta, Kevan C. Herold, Marjana Marinac

Diabetes 2024;73(6):823–833

https://doi.org/10.2337/dbi23-0012

Published: 13 February 2024

View article titled, Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes

Meeting Abstracts

731-P: The Effect of Abatacept upon Glucose and C-Peptide Endpoints at One Year of Treatment and on Follow-up

EMILY K. SIMS, WILLIAM E. RUSSELL, KEVAN C. HEROLD, JAY SOSENKO

Diabetes 2023;72(Supplement_1):731-P

https://doi.org/10.2337/db23-731-P

Published: 20 June 2023

View article titled, 731-P: The Effect of Abatacept upon Glucose and C-Peptide Endpoints at One Year of Treatment and on Follow-up

Journal Articles

The β-Cell in Type 1 Diabetes Pathogenesis: A Victim of Circumstances or an Instigator of Tragic Events?

Roberto Mallone, Clémentine Halliez, Jinxiu Rui, Kevan C. Herold

Diabetes 2022;71(8):1603–1610

https://doi.org/10.2337/dbi21-0036

Published: 21 August 2022

View article titled, The β-Cell in Type 1 Diabetes Pathogenesis: A Victim of Circumstances or an Instigator of Tragic Events?

Journal Articles

Carbonyl Posttranslational Modification Associated With Early-Onset Type 1 Diabetes Autoimmunity

Mei-Ling Yang, Sean E. Connolly, Renelle J. Gee, TuKiet T. Lam, Jean Kanyo, Jian Peng, Perrin Guyer, Farooq Syed, Hubert M. Tse, Steven G. Clarke, Catherine F. Clarke, Eddie A. James, Cate Speake, Carmella Evans-Molina, Peter Arvan, Kevan C. Herold, Li Wen, Mark J. Mamula

Diabetes 2022;71(9):1979–1993

https://doi.org/10.2337/db21-0989

Published: 22 June 2022

View article titled, Carbonyl Posttranslational Modification Associated With Early-Onset Type 1 Diabetes Autoimmunity

Journal Articles

Indirect and Direct Effects of SARS-CoV-2 on Human Pancreatic Islets

Diabetes 2022;71(7):1579–1590

https://doi.org/10.2337/db21-0926

Published: 02 May 2022

View article titled, Indirect and Direct Effects of SARS-CoV-2 on Human Pancreatic Islets

Journal Articles

Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective

Emily K. Sims, Rachel E.J. Besser, Colin Dayan, Cristy Geno Rasmussen, Carla Greenbaum, Kurt J. Griffin, William Hagopian, Mikael Knip, Anna E. Long, Frank Martin, Chantal Mathieu, Marian Rewers, Andrea K. Steck, John M. Wentworth, Stephen S. Rich, Olga Kordonouri, Anette-Gabriele Ziegler, Kevan C. Herold, for the NIDDK Type 1 Diabetes TrialNet Study Group

Diabetes 2022;71(4):610–623

https://doi.org/10.2337/dbi20-0054

Published: 22 March 2022

View article titled, Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective

Journal Articles

The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes

Emily K. Sims, David Cuthbertson, Kevan C. Herold, Jay M. Sosenko

Diabetes 2021;70(12):2922–2931

https://doi.org/10.2337/db21-0519

Published: 22 September 2021

View article titled, The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes

Meeting Abstracts

1117-P: Characterizing Glucose/C-Peptide Response Curve (GCRC) Phenotypes to Enhance Selection Specificity for Type 1 Diabetes (T1D) Prevention Trials

HEBA M. ISMAIL, DAVID D. CUTHBERTSON, MARIA J. REDONDO, CARMELLA EVANS-MOLINA, ANDREA STECK, HENRY RODRIGUEZ, STEPHEN E. GITELMAN, KEVAN C. HEROLD, JAY S. SKYLER, BRANDON M. NATHAN, MARK A. ATKINSON, LINDA DIMEGLIO, JAY SOSENKO

Diabetes 2021;70(Supplement_1):1117-P

https://doi.org/10.2337/db21-1117-P

Published: 01 June 2021

View article titled, 1117-P: Characterizing Glucose/C-Peptide Response Curve (GCRC) Phenotypes to Enhance Selection Specificity for Type 1 Diabetes (T1D) Prevention Trials

Meeting Abstracts

11-OR: Assessments of Prediagnostic Metabolic Measures as Surrogate Endpoints for Type 1 Diabetes (T1D) Prevention Trials

EMILY K. SIMS, DAVID D. CUTHBERTSON, LAURA M. JACOBSEN, KEVAN C. HEROLD, JAY SOSENKO

Diabetes 2021;70(Supplement_1):11-OR

https://doi.org/10.2337/db21-11-OR

Published: 01 June 2021

View article titled, 11-OR: Assessments of Prediagnostic Metabolic Measures as Surrogate Endpoints for Type 1 Diabetes (T1D) Prevention Trials

Meeting Abstracts

348-OR: Metabolic Phenotype of Autoantibody Positive (AbPos) Long-Term Nonprogressors (LTNPs) to Type 1 Diabetes (T1D)

CARMELLA EVANS-MOLINA, ZEB I. SAEED, JAY SOSENKO, MARK A. ATKINSON, KEVAN C. HEROLD, HEBA M. ISMAIL, HELENA ELDING LARSSON, MARKUS LUNDGREN, ANTOINETTE MORAN, DANIEL J. MOORE, BRANDON M. NATHAN, JERRY P. PALMER, EMILY K. SIMS, ANDREA STECK, DIANE K. WHERRETT, MARIA J. REDONDO

Diabetes 2020;69(Supplement_1):348-OR

https://doi.org/10.2337/db20-348-OR

Published: 01 June 2020

View article titled, 348-OR: Metabolic Phenotype of Autoantibody Positive (AbPos) Long-Term Nonprogressors (LTNPs) to Type 1 Diabetes (T1D)

Meeting Abstracts

99-OR: An Inflection Point (IP) of C-Peptide (C-P) Decline during Progression to Type 1 Diabetes (T1D)

HEBA M. ISMAIL, JAY S. SKYLER, JAY SOSENKO, JERRY P. PALMER, CARMELLA EVANS-MOLINA, LINDA DIMEGLIO, MARIA J. REDONDO, ANDREA STECK, MARK A. ATKINSON, KEVAN C. HEROLD, BRANDON M. NATHAN

Diabetes 2020;69(Supplement_1):99-OR

https://doi.org/10.2337/db20-99-OR

Published: 01 June 2020

View article titled, 99-OR: An Inflection Point (IP) of C-Peptide (C-P) Decline during Progression to Type 1 Diabetes (T1D)

Meeting Abstracts

277-OR: Teplizumab Reverses the Loss of C-Peptide in Relatives at Risk for Type 1 Diabetes (T1D)

EMILY K. SIMS, BRIAN N. BUNDY, KENNETH D. STIER, ELISAVET SERTI, NOHA LIM, GERALD T. NEPOM, CARMELLA EVANS-MOLINA, KEVAN C. HEROLD

Diabetes 2020;69(Supplement_1):277-OR

https://doi.org/10.2337/db20-277-OR

Published: 01 June 2020

View article titled, 277-OR: Teplizumab Reverses the Loss of C-Peptide in Relatives at Risk for Type 1 Diabetes (T1D)

Meeting Abstracts

276-OR: A 2-Dimensional (2D) Analysis of Glucose and C-Peptide Shows a Teplizumab Effect in Individuals at Risk for Type 1 Diabetes (T1D) 3 Months after Treatment

EMILY K. SIMS, MEGAN V. WARNOCK, KEVAN C. HEROLD, JAY SOSENKO

Diabetes 2020;69(Supplement_1):276-OR

https://doi.org/10.2337/db20-276-OR

Published: 01 June 2020

View article titled, 276-OR: A 2-Dimensional (2D) Analysis of Glucose and C-Peptide Shows a Teplizumab Effect in Individuals at Risk for Type 1 Diabetes (T1D) 3 Months after Treatment

Meeting Abstracts

1618-P: Insulin Secretion Variability According to the Specific Type 1 Diabetes (T1D) Risk Predictor

LAURA M. JACOBSEN, BRANDON M. NATHAN, HEBA M. ISMAIL, MARIA J. REDONDO, DESMOND SCHATZ, MICHAEL J. HALLER, EMILY K. SIMS, JAY S. SKYLER, JERRY P. PALMER, KEVAN C. HEROLD, JAY SOSENKO

Diabetes 2020;69(Supplement_1):1618-P

https://doi.org/10.2337/db20-1618-P

Published: 01 June 2020

View article titled, 1618-P: Insulin Secretion Variability According to the Specific Type 1 Diabetes (T1D) Risk Predictor

NARROW

Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop

70-OR: PROTECT Per-Protocol Analysis—Preserving ß-Cell Function in Children and Adolescents with Newly Diagnosed Stage 3 Type 1 Diabetes (T1D)

155-OR: Genetic Variation and Time to Progression in TN10 (Teplizumab)

1301-P: Frequency of Single Autoantibody Positivity (SAB+) Varies by Race/Ethnicity and Area Deprivation Index in Individuals at Risk for Type 1 Diabetes (T1D)

68-OR: Influence of the Type 1 Diabetes Genetic Risk Score on Response to Immunotherapies for Type 1 Diabetes Prevention

728-P: Experience with Teplizumab in the PROTECT Type 1 Diabetes (T1D) Study during the COVID-19 Pandemic

Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes

731-P: The Effect of Abatacept upon Glucose and C-Peptide Endpoints at One Year of Treatment and on Follow-up

The β-Cell in Type 1 Diabetes Pathogenesis: A Victim of Circumstances or an Instigator of Tragic Events?

Carbonyl Posttranslational Modification Associated With Early-Onset Type 1 Diabetes Autoimmunity

Indirect and Direct Effects of SARS-CoV-2 on Human Pancreatic Islets

Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective

The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes

1117-P: Characterizing Glucose/C-Peptide Response Curve (GCRC) Phenotypes to Enhance Selection Specificity for Type 1 Diabetes (T1D) Prevention Trials

11-OR: Assessments of Prediagnostic Metabolic Measures as Surrogate Endpoints for Type 1 Diabetes (T1D) Prevention Trials

348-OR: Metabolic Phenotype of Autoantibody Positive (AbPos) Long-Term Nonprogressors (LTNPs) to Type 1 Diabetes (T1D)

99-OR: An Inflection Point (IP) of C-Peptide (C-P) Decline during Progression to Type 1 Diabetes (T1D)

277-OR: Teplizumab Reverses the Loss of C-Peptide in Relatives at Risk for Type 1 Diabetes (T1D)

276-OR: A 2-Dimensional (2D) Analysis of Glucose and C-Peptide Shows a Teplizumab Effect in Individuals at Risk for Type 1 Diabetes (T1D) 3 Months after Treatment

1618-P: Insulin Secretion Variability According to the Specific Type 1 Diabetes (T1D) Risk Predictor

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only